Xilio Therapeutics, Inc. (XLO) Misses Q2 EPS by 1c

Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q2 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $30 million.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• William Blair Starts Arlo Technologies (ARLO) at Outperform
• Increasing unusual call option volume: PEW OPRA VERA JACK IMVT XP LRN STRC DOMO EIX